Earnings ·
DBV Technologies reported Second Quarter and Half-Year 2026 financial results, reporting a net loss of $98.0 million…
DBVTFDBV Technologies S.A.
DBV Technologies reported Second Quarter and Half-Year 2026 financial results, reporting a net loss of $98.0 million for the six months ended June 30, 2026, compared to $69.0 million for the same period in 2025. The company anticipates an anticipated BLA submission for the VIASKIN Peanut Patch in children aged 4 through 7 years in the third quarter of 2026. As of June 30, 2026, the company holds $174.9 million in cash and cash equivalents, which is expected to support operations into the third quarter of 2027. DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions.